Sensei Biotherapeutics, Inc.

SNSE Nasdaq CIK: 0001829802

Company Information

Industry Pharmaceutical Preparations
SIC Code 2834
Entity Type operating
SEC Category Non-accelerated filerSmaller reporting companyEmerging growth company
State of Incorporation DE
Business Address 1405 RESEARCH BLVD, SUITE 125, ROCKVILLE, MD, 20850
Mailing Address 1405 RESEARCH BLVD, SUITE 125, ROCKVILLE, MD, 20850
Phone (240) 243-8000
Fiscal Year End 1231
EIN 000000000

Financial Overview

FY2025

-$21.09M
Net Income
$6.97M
Total Liabilities
$64.89M
Stockholders' Equity
$9.99M
Cash & Equivalents
$-16.72
EPS

Recent SEC Filings

Form Type Date Filed Document
8-K Current report of material events March 30, 2026 View on SEC
10-K Annual financial report March 30, 2026 View on SEC
SCHEDULE 13G Passive beneficial ownership (>5%) February 25, 2026 View on SEC
4 Insider stock transaction report February 19, 2026 View on SEC
3 Initial insider ownership report February 19, 2026 View on SEC
8-K Current report of material events February 18, 2026 View on SEC
4 Insider stock transaction report February 17, 2026 View on SEC
3 Initial insider ownership report February 17, 2026 View on SEC
8-K Current report of material events February 13, 2026 View on SEC
8-K Current report of material events December 23, 2025 View on SEC

Annual Reports

10-K March 30, 2026
  • Acquired Faeth Therapeutics to pivot focus toward metabolism-based cancer therapies.
  • Lead drug candidate PIKTOR (FT-101) targets solid tumors with Phase 2 results expected in late 2026.
View Analysis

Material Events

8-K Acquisition March 30, 2026
High Impact
  • Strategic acquisition of Faeth Therapeutics pivots company to metabolic-oncology.
  • PIKTOR (FT-101) established as the new lead clinical-stage asset.
View Analysis

Insider Trading

STRONG SELL 2 insiders 16 recent transactions
View Full Insider Trading Profile

Related Companies

Companies in the same industry (SIC: 2834)

Investor Resources

Learn more about SEC filings and how to research public companies.

Important Disclaimer

This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.